4.5 Article

A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting

期刊

MABS
卷 3, 期 1, 页码 21-30

出版社

TAYLOR & FRANCIS INC
DOI: 10.4161/mabs.3.1.14057

关键词

leukemia; natural killer cells; antibody-derivatives; dual targeting; sctb

资金

  1. DFG (Deutsche Forschungsgemeinschaft
  2. German Research Community) [SFB 643, C6, C8, GK592]
  3. Bayerische Eliteforderung (Bavarian Scholarship Foundation)
  4. German Jose-Carreras Leukemia-Foundation [DJCLS F07/03]
  5. Wilhelm Sander Foundation, Neustadt, Germany [2007.049.1]
  6. Stiftung Deutsche Krebshilfe [108242]
  7. Beitlich Foundation, Tubingen
  8. Association 'Kaminkehrer helfen krebskranken Kindern'

向作者/读者索取更多资源

A single-chain triplebody (sctb) 33-ds16-ds19 comprising two distal single-chain Fv fragments (scFvs) specific for the lymphoid antigen CD19 and the myeloid antigen CD33 flanking a central scFv specific for CD16, which is the low affinity Fc-receptor (Fe gamma RIII) present on natural killer cells and macrophages, was produced and its properties were investigated. CD33 and CD19 in combination are present on acute leukemiablasts with mixed lineage phenotype, but not on normal human hematopoietic cells. For comparison, two bispecific scFvs (bsscFvs), ds19-ds16 and 33-ds16, with monovalent binding to CD19 and CD33, respectively, were also studied. The sctb 33-ds16-ds19 specifically interacted with all three antigens. On the antigen double-positive cell line BV-173, the sctb bound with 2-fold greater avidity than bsscFv ds19-ds16 (K-D = 21 vs. 42 nM) and with 1.4-fold greater avidity than bsscFv 33-ds16 (K-D = 29 nM). All three fusion proteins had similar affinity for CD16 and sufficient thermic stability in human serum. In antibody-dependent cellular cytotoxicity (ADCC) reactions with human mononuclear cells as effectors, the sctb promoted lysis of BV-173 cells at 23-fold lower concentrations than bsscFv ds19-ds16 and at 1.4-fold lower concentrations than bsscFv 33-ds16. The sctb also mediated potent ADCC of the antigen double-positive mixed lineage leukemia cell line SEM, and the half-maximal concentration EC50 for BV-173 cells was 7 pM. Therefore, CD19 and CD33 are present on the surface of these leukemic cell lines such that they can be connected by a single sctb molecule, permitting the recruitment of NK cells via CD16 and tumor cell lysis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy

Katja Klausz, Michael Cieker, Christian Kellner, Thies Roesner, Anna Otte, Steffen Krohn, Anja Lux, Falk Nimmerjahn, Thomas Valerius, Martin Gramatzki, Matthias Peipp

Summary: The novel therapeutic antibody TP15, targeting ICAM-1, showed significant anti-tumor activity by inducing antibody-dependent cell-mediated cytotoxicity. It prevented myeloma cell engraftment and prolonged survival in a mouse model, demonstrating potential for myeloma immunotherapy.

HAEMATOLOGICA (2021)

Article Oncology

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions

Niklas Baumann, Thies Roesner, J. H. Marco Jansen, Chilam Chan, Klara Marie Eichholz, Katja Klausz, Dorothee Winterberg, Kristina Mueller, Andreas Humpe, Renate Burger, Matthias Peipp, Denis M. Schewe, Christian Kellner, Jeanette H. W. Leusen, Thomas Valerius

Summary: The study shows that inhibiting glutaminyl cyclase can enhance the immunotherapeutic effects on tumor cells. Inhibition of glutaminyl cyclase reduces the specific signal of CD47 at the SIRP alpha binding site, leading to increased efficiency of tumor cell phagocytosis and ADCC reactions mediated by antibodies.

CANCER SCIENCE (2021)

Article Biochemistry & Molecular Biology

Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen

Christian Kellner, Sebastian Lutz, Hans-Heinrich Oberg, Daniela Wesch, Anna Otte, Katarina J. Diemer, Hauke Wilcken, Dirk Bauerschlag, Claus-Christian Glueer, Christian Wichmann, Dieter Kabelitz, Jeanette H. W. Leusen, Katja Klausz, Andreas Humpe, Martin Gramatzki, Matthias Peipp

Summary: Combining NKG2D ligand ULBP2 with HER2-targeting scFv can effectively trigger NK cell killing of HER2-positive breast cancer cells. This immunoligand not only induces tumor cell lysis, but also enhances antibody-dependent cell-mediated cytotoxicity against tumor cells.

BIOLOGICAL CHEMISTRY (2022)

Meeting Abstract Hematology

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Katja Klausz, Carina Lynn Gehlert, Ammelie Svea Boje, Marta Lustig, Steffen Krohn, Syeda Maliha Ahmed, Christian Kellner, Thomas Valerius, Lenka Besse, Andrej Besse, Christoph Driessen, Martin Gramatzki, Matthias Peipp

Article Oncology

The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In Vivo

Katja Klausz, Christian Kellner, Carina Lynn Gehlert, Steffen Krohn, Hauke Wilcken, Inken Floerkemeier, Andreas Guenther, Dirk O. Bauerschlag, Bernd Clement, Martin Gramatzki, Matthias Peipp

Summary: P8-D6 is a novel dual inhibitor that demonstrates broad anti-tumor activity by inhibiting the growth and inducing apoptosis of myeloma cells. It shows low toxicity to healthy cells and significantly inhibits tumor growth in xenograft models. This study highlights the potential of P8-D6 as a promising therapeutic agent for multiple myeloma.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Hematology

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Kristina Mueller, Fotini Vogiatzi, Dorothee Winterberg, Thies Rosner, Lennart Lenk, Lorenz Bastian, Carina L. Gehlert, Marie-Pauline Autenrieb, Monika Bruggemann, Gunnar Cario, Martin Schrappe, Andreas E. Kulozik, Cornelia Eckert, Anke K. Bergmann, Beat Bornhauser, Jean-Pierre Bourquin, Thomas Valerius, Matthias Peipp, Christian Kellner, Denis M. Schewe

Summary: This study suggests that combining CD47 blockade with Dara is a promising therapy for T-ALL, especially for relapsed/refractory disease harboring a dismal prognosis in patients.
Review Immunology

Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer

Matthias Peipp, Katja Klausz, Ammelie Svea Boje, Tobias Zeller, Stefan Zielonka, Christian Kellner

Summary: NK cells play a crucial role in cancer immune surveillance by recognizing malignant cells and controlling their activation through the expression of activating and inhibitory receptors. The recruitment and activation of NK cells have great potential in cancer treatment. Targeting the ligands expressed on tumors is also a promising approach to unleash the cytotoxicity of NK cells.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2022)

Article Immunology

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Niklas Baumann, Christian Arndt, Judith Petersen, Marta Lustig, Thies Roesner, Katja Klausz, Christian Kellner, Miriam Bultmann, Lorenz Bastian, Fotini Vogiatzi, Jeanette H. W. Leusen, Renate Burger, Denis M. Schewe, Matthias Peipp, Thomas Valerius

Summary: Antibody-based immunotherapy is increasingly used to treat acute lymphoblastic leukemia (ALL) patients. This study investigates the effects of CD38 antibodies, targeting T-ALL cells expressing CD38, on tumor cell killing through antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cell-mediated cytotoxicity (ADCC). The study shows that IgA2 variants of CD38 antibodies are more effective in killing tumor cells through myeloid cells. The interactions between CD47 and SIRP alpha negatively regulate ADCP and ADCC. Additionally, treatment with all-trans retinoic acid (ATRA) enhances CD38 expression and further enhances ADCP and ADCC.

FRONTIERS IN IMMUNOLOGY (2022)

Article Hematology

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis

Fotini Vogiatzi, Julia Heymann, Kristina Muller, Dorothee Winterberg, Aneta Drakul, Thies Rosner, Lennart Lenk, Michelle Heib, Carina Lynn Gehlert, Gunnar Cario, Martin Schrappe, Alexander Claviez, Beat Bornhauser, Jean-Pierre Bourquin, Simon Bomken, Dieter Adam, Fabian-Simon Frielitz, Britta Maecker-Kolhoff, Martin Stanulla, Thomas Valerius, Matthias Peipp, Christian Kellner, Denis M. Schewe

Summary: The addition of the Bcl-2 inhibitor venetoclax enhances the efficacy of therapeutic antibodies by increasing antibody-dependent cellular phagocytosis mediated by macrophages.

BLOOD ADVANCES (2022)

Article Immunology

Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody

Carina Lynn Gehlert, Pegah Rahmati, Ammelie Svea Boje, Dorothee Winterberg, Steffen Krohn, Thomas Theocharis, Elisa Cappuzzello, Anja Lux, Falk Nimmerjahn, Ralf J. Ludwig, Marta Lustig, Thies Roesner, Thomas Valerius, Denis Martin Schewe, Christian Kellner, Katja Klausz, Matthias Peipp

Summary: This study engineered a CD19 antibody to enhance effector cell-mediated killing and CDC activity. The dual optimized CD19 antibody showed improved ADCC, ADCP, and CDC compared to the non-engineered antibody. This finding is crucial for improving CD19-directed cancer immunotherapy.

FRONTIERS IN IMMUNOLOGY (2022)

Article Immunology

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages

Tobias Zeller, Sebastian Lutz, Ira A. Muennich, Roland Windisch, Patricia Hilger, Tobias Herold, Natyra Tahiri, Jan C. Banck, Oliver Weigert, Andreas Moosmann, Michael Von Bergwelt-Baildon, Cindy Flamann, Heiko Bruns, Christian Wichmann, Niklas Baumann, Thomas Valerius, Denis M. Schewe, Matthias Peipp, Thies Roesner, Andreas Humpe, Christian Kellner

Summary: Blocking both CD47 and LILRB1 can enhance the phagocytosis of lymphoma cells by macrophages, improving the efficacy of antibody therapy for chronic lymphocytic leukemia and lymphomas.

FRONTIERS IN IMMUNOLOGY (2022)

Meeting Abstract Hematology

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Alexander Biedermann, Doris Mangelberger-Eberl, Dimitrios Mougiakakos, Maike Buettner-Herold, Cindy Flamann, Christian Kellner, Sarah Altmeyer, Joerg Bittenbring, Christian Augsberger, Maria Patra-Kneuer, Karin Landgraf, Kristina Ilieva-Babinsky, Stefan Haskamp, Fabian Beier, Simon Voelkl, Christian Pallasch, Benedikt Jacobs, Stefan Steidl, Christina Heitmueller, Andreas Mackensen, Heiko Bruns

Article Biotechnology & Applied Microbiology

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia

Adrian Gottschlich, Moritz Thomas, Ruth Gruenmeier, Stefanie Lesch, Lisa Rohrbacher, Veronika Igl, Daria Briukhovetska, Mohamed-Reda Benmebarek, Binje Vick, Sertac Dede, Katharina Mueller, Tao Xu, Dario Dhoqina, Florian Maerkl, Sophie Robinson, Andrea Sendelhofert, Heiko Schulz, Oeykue Umut, Vladyslav Kavaka, Christina Angeliki Tsiverioti, Emanuele Carlini, Sayantan Nandi, Thaddaeus Strzalkowski, Theo Lorenzini, Sophia Stock, Philipp Jie Mueller, Janina Doerr, Matthias Seifert, Bruno L. Cadilha, Ruben Brabenec, Natalie Roeder, Felicitas Rataj, Manuel Nueesch, Franziska Modemann, Jasmin Wellbrock, Walter Fiedler, Christian Kellner, Eduardo Beltran, Tobias Herold, Dominik Paquet, Irmela Jeremias, Louisa von Baumgarten, Stefan Endres, Marion Subklewe, Carsten Marr, Sebastian Kobold

Summary: A single-cell screening approach has identified specific gene targets for CAR-T cell therapy in acute myeloid leukemia (AML). These targets, specifically expressed on malignant cells but lacking on healthy cells, have shown strong efficacy and minimal toxicity in in vitro and in vivo experiments.

NATURE BIOTECHNOLOGY (2023)

Meeting Abstract Oncology

Single sequencing-based development of chimeric antigen receptor (CAR) T cells for the treatment of acute myeloid leukemias

A. Gottschlich, M. Thomas, R. Grunmeier, S. Lesch, L. Igl V. Rohrbacher, D. Briukhovetska, M. R. Benmebarek, S. Dede, K. Muller, T. Xu, D. Dhoqina, O. Umut, F. Markl, S. Robinson, H. Schulz, B. Vick, B. Cadilha, R. Brabenec, N. Roder, F. Rataj, M. Nuesch, J. Wellbrock, F. Modemann, W. Fiedler, C. Kellner, D. Paquet, I. Jeremias, L. Von Baumgarten, S. Endres, M. Subklewe, C. Marc, S. Kobold

ONCOLOGY RESEARCH AND TREATMENT (2022)

Meeting Abstract Oncology

Enhancement of CD38 antibody-mediated phagocytosis of TALL cells by Fc engineering and CD47 blockade

P. Hilger, T. Zeller, F. Vogiatzi, K. Mueller, I. A. Muennich, R. Windisch, C. Wichmann, F. Nimmerjahn, T. Valerius, M. Peipp, A. Humpe, D. M. Schewe, C. Kellner

ONCOLOGY RESEARCH AND TREATMENT (2022)

暂无数据